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Drug discovery and development is a complex, lengthy
process and failure of a candidate molecule can occur as a
result of a combination of reasons, such as poor pharma-
cokinetics, lack of efficacy or toxicity. Drugs compromise
the numerous, sometimes competing objectives so that
the benefits to patients outweigh potential drawbacks and
risks [1]. De novo drug design, involves searching an
immense space of feasible, drug-like molecules to select
those with the highest chances of becoming drugs using
computational technology [2]. Traditionally, de novo
design has focused on designing molecules satisfying a
single objective, such as a similarity value to a known lig-
and or a virtual screening score, and ignored the presence
of the multiple objectives required for drug-like behavior.
Recently, methods have appeared in the literature that
attempt to design molecules satisfying multiple prede-
fined objectives [3]. In this presentation we briefly review
these methods and then describe a new multi-objective
optimization de novo design algorithm that combines evo-
lutionary techniques with graph-theory to directly manip-
ulate molecular graphs and design structurally diverse
molecules satisfying one or more objectives.
In our experimental section we present results obtained
from applying the method to design molecules with a
desired biological profile with the primary constraint
based on a set of known ligands. The implementation of
the algorithm includes an initial step where the supplied
ligand dataset is analyzed to extract and characterize fre-
quently occurring molecular subgraphs. The resulting
subgraphs together with other predefined elements form
the molecular building blocks used by the algorithm. In
subsequent steps a set of initial molecular graphs is pre-
pared and subjected to an evolutionary process that
involves fitness calculation against each objective, identi-
fication of a compromise surface (also known as Pareto-
ranking), parent selection, mutation and crossover. Fit-
ness calculation focuses on pharmacophoric similarity
with the known ligands while parent selection uses a
graph-based diversity method in order to preserve struc-
tural diversity of the evolved molecules. Our findings
indicate that the proposed algorithm produces compro-
mising solutions of substantial structural diversity and
can thus be used for an efficient search of the pharmaco-
logically interesting chemical space as defined by the sup-
plied ligands and constrained by the objectives defined.
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